

Dealdoc

Distribution agreement for CanGaroo Bio Envelope

Aziyo Biologics Biotronik

Apr 19 2018

Distribution agreement for CanGaroo Bio Envelope

Companies:	Aziyo Biologics
	Biotronik
Announcement date:	Apr 19 2018
Deal value, US\$m:	n/d

- Details
- Financials
- Termsheet
- Press Release
- Filing Data
- <u>Contract</u>

Details

Announcement date:	Apr 19 2018
Industry sectors:	Medical device
Brand name:	CanGaroo Bio Envelope
Asset type:	Product
Therapy areas:	Cardiovascular
Technology types:	Devices » Surgical devices
	Implant
Deal components:	Distribution
Stages of development:	Marketed
Geographic focus:	North America » United States

Financials

Deal value, US\$m:

n/d

Termsheet

Aziyo Biologics has entered into a US co-distribution agreement for its CanGaroo Bio Envelope with BIOTRONIK.

CanGaroo is available in five sizes for use with the full spectrum of transvenous and subcutaneous CIEDs.

Per the strategic distribution agreement, BIOTRONIK is selling all five sizes in the United States branded as Bio Envelope.

Press Release

Aziyo Announces CanGaroo Strategic Co-Distribution Agreement with BIOTRONIK US

SILVER SPRING, Md.--(BUSINESS WIRE)-- Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced that it has entered into a US co-distribution agreement for its CanGaroo® Bio Envelope with BIOTRONIK, Inc., a global leader in cardio- and endovascular medical technology.

CanGaroo Bio Envelopes are a natural extracellular matrix (ECM) scaffold that securely hold cardiovascular implantable electronic devices (CIEDs) to create a stable environment following implantation. In vivo studies have demonstrated that use of CanGaroo when implanting CIEDs reduces the risk of device migration and erosion and may facilitate device removal when future exchange or revision is required.

"BIOTRONIK is trusted and respected by hospitals, physicians and patients, and our distribution partnership expands access to a meaningful cardiovascular solution," said Andrew Green, Aziyo's EVP and General Manager of Cardiovascular Products. "Our ECM envelopes help deliver the best possible patient care and can reduce cost, providing advantages that complement BIOTRONIK's comprehensive portfolio of cardiac rhythm management devices. This partnership changes the landscape of cardiac care."

CanGaroo is available in five sizes for use with the full spectrum of transvenous and subcutaneous CIEDs. Per the strategic distribution agreement, BIOTRONIK is selling all five sizes in the United States branded as Bio Envelope.

About Aziyo Biologics, Inc. Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015, the company has expanded through acquisitions and strategic partnerships, creating a high-growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties.

About CanGaroo® Bio Envelope

The CanGaroo Bio Envelope is constructed from multi-laminate sheets of decellularized, non-crosslinked, lyophilized extracellular matrix (ECM) derived from porcine small intestinal submucosa (SIS). Once implanted, CanGaroo secures the CIED in place, and evidence shows that over time it remodels into a vascularized pocket that may facilitate CIED removal or revision. CanGaroo Bio Envelope is a 510(k) FDA-cleared medical device.

About Porcine SIS-ECM

Porcine SIS-ECM is a decellularized matrix that serves as a bioscaffold to allow vascular ingrowth from adjacent tissues to deliver progenitor cells and nutrients to the matrix, which then differentiate into tissue-specific cells and structures. The ECM is gradually replaced as the patient's own cells restore the diseased or damaged site. During repair, the matrix is naturally degraded and resorbed, leaving remodeled functional tissue where damaged or injured tissue would normally be expected. Since 1999, an estimated two million patients worldwide have received SIS-ECM implants.

Filing Data

Not available.

Contract

Not available.